Zacks Investment Research
29 Sept 2026, 13:51 UTC · 1h ago
Verdict
Headline takes no side. We score TEVA +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Teva expects combined sales of Austedo, Ajovy, and Uzedy to reach approximately $3.7 billion in 2026.
Priced inanalysis of previous targets
So whatThis represents 17% growth at the midpoint, shifting the revenue mix toward higher-margin branded assets.
More positive than 87% of claims this week
Austedo's 2026 revenue guidance of $2.45-$2.60 billion suggests the drug is roughly a year ahead of its previous $2.5 billion target for 2027.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced inanalysis of previous targets
So whatAccelerated adoption suggests higher EPS contributions in FY2026 than previously modeled by analysts.
More positive than 79% of claims this week
Combined sales of Austedo, Ajovy, and Uzedy rose 43% year over year to more than $1 billion in the second quarter.
Priced inanalysis of Q2 results
More positive than 66% of claims this week
Teva expects Austedo revenues to exceed $3 billion by 2030.
Priced inlong-term guidance
So whatThis long-term target provides a valuation floor for the branded franchise over the next four years.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company is seeing strong growth in its branded drugs segment with sales increasing 43% year over year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
5h ago
+0.5%
Price flat so far
$39.06 vs $38.88 close before publication (Sep 28) · not market-adjusted
TEVA chart →
